Seeking Alpha: Betting Big on GNC

Michael Wiggins De Oliveira, author at Seeking Alpha, discusses health supplement retailer GNC as his "Idea of the Month." He notes that even though the company is in debt by more than $1 billion, it's still a buy for him because of the measures the company is taking to wipe out the debt, including the $200 million in annual free cash flow.

More In Business

Americans Ramped Up Spending During the Holidays Despite Some Financial Anxiety and Higher Costs

Mastercard SpendingPulse said Tuesday that holiday sales rose this year.

On the Scene: Post-Holiday Shopping at American Dream Mall

New Jersey's American Dream Mall continues to offer holiday experiences.

Maine Storm Has Delayed a Key Vote on California-Style Limits for Gas Vehicles

The rollout of potential new electric vehicle goals in Maine has been pushed back by a year because of a recent storm.

Tips on How to Return Unwanted Gifts

Tips on How to Return Unwanted Gifts

What Investors Are Looking Ahead to This Week

What Investors Are Looking Ahead to This Week

Holiday Travel Mostly Uninterrupted Across U.S.

Holiday Travel Mostly Uninterrupted Across U.S.

Holiday Travel Mostly Nice, but With Some Naughty Disruptions Again on Southwest Airlines

Conditions have been mostly nice for travelers flying ahead of and on Christmas Day, but some naughty disruptions plagued those flying with Southwest Airlines again this year.

The Secret Life of Gift Cards: Here's What Happens to the Billions That Go Unspent Each Year

Gift cards make great stocking stuffers — just as long as you don't stuff them in a drawer and forget about them after the holidays.

Big Business This Week: Warner Bros Discovery + Paramount Rumor, Steel Titans Deal and More

Big Business This Week is a guided tour through the biggest market stories of the week, from winning stocks to brutal dips to the facts and forecasts generating buzz on Wall Street.

Bristol Myers Squibb to Buy Koruna Therapeutics for $14 Billion

Bristol Myers Squibb agreed to buy schizophrenia drug maker Karuna Therapeutics in a $14 billion deal.

Load More